Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives.

The vonoprazan (VPZ) triple therapy regimen for Helicobacter pylori (H. pylori) eradication developed by Han et al employs a scientifically rigorous clinical trial design. This multicenter randomized controlled trial establishes a standardized treatment framework aimed at improving H. pylori eradication rates, focusing on simplifying treatment regimens, shortening therapy duration, and optimizing therapeutic outcomes. The core of clinical translation lies in improving drug accessibility, establishing multidimensional safety evaluation systems, and optimizing cost-effectiveness. Conducting regional adaptability studies and comprehensive safety assessments is crucial for enhancing VPZ regimen effectiveness in China's diverse healthcare environments. This study provides important evidence-based support for optimizing H. pylori treatment strategies in China, though further validation of universal applicability for nationwide implementation remains necessary.